Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||43.07%||Sales Growth - Q/Q||27.68%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-80.97%||ROE||156.1%||ROI||-102.16%|
|Current Ratio||2.13||Quick Ratio||2.09||Long Term Debt/Equity||5.49||Debt Ratio||-0.4|
|Gross Margin||91.55%||Operating Margin||-615.77%||Net Profit Margin||-774.12%||Dividend Payout Ratio|
|Cash From Financing Activities||-220 K||Cash From Investing Activities||49.9 M||Cash From Operating Activities||-45.09 M||Gross Profit||8.62 M|
|Net Profit||-35.17 M||Operating Profit||-22.76 M||Total Assets||282.93 M||Total Current Assets||125.04 M|
|Total Current Liabilities||58.68 M||Total Debt||368.43 M||Total Liabilities||429.69 M||Total Revenue||9.39 M|
|High 52 week||24.76||Low 52 week||13.65||Last close||16.79||Last change||2.5%|
|RSI||23.17||Average true range||0.64||Beta||1.52||Volume||4.05 M|
|Simple moving average 20 days||-5.57%||Simple moving average 50 days||-12.22%||Simple moving average 200 days||-20.29%|
|Performance Week||1.63%||Performance Month||-13.01%||Performance Quart||-22.66%||Performance Half||-26.52%|
|Performance Year||3.39%||Performance Year-to-date||-14.64%||Volatility daily||1.91%||Volatility weekly||4.26%|
|Volatility monthly||8.74%||Volatility yearly||30.26%||Relative Volume||263.48%||Average Volume||2.6 M|
|New High||New Low|
2020-05-28 06:58:47 | Is There An Opportunity With Exelixis, Inc.'s NASDAQ:EXEL 49% Undervaluation?
2020-05-20 13:30:14 | 3 Charts That Suggest Biotech Stocks Are Headed Higher
2020-05-13 09:54:00 | Better Buy: bluebird bio vs. Exelixis
2020-05-06 16:05:00 | Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
2020-05-06 11:40:03 | Exelixis EXEL Q1 Earnings and Revenues Surpass Estimates
2020-05-06 05:23:49 | Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT
2020-05-06 01:01:17 | Exelixis Inc EXEL Q1 2020 Earnings Call Transcript
2020-05-05 18:25:10 | Exelixis EXEL Q1 Earnings and Revenues Beat Estimates
2020-05-05 16:05:00 | Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-05 15:00:00 | Exelixis, Inc. to Host Earnings Call
2020-05-01 13:14:00 | Exelixis Charts Are Pointed Higher, Look to Buy a Dip
2020-04-28 12:33:04 | Earnings Preview: Exelixis EXEL Q1 Earnings Expected to Decline
2020-04-22 10:30:02 | Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
2020-04-21 16:05:00 | Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020
2020-04-21 12:59:04 | Company News for Apr 21, 2020
2020-04-21 12:43:00 | Exelixis Stock Strength Jumps On Positive Cancer Treatment Results
2020-04-20 16:19:23 | This Biotech Stock Just Blew Into A Profit-Taking Zone — Here's Why
2020-04-20 11:03:00 | Kidney Cancer Drug From Bristol-Myers and Exelixis Meets Key Phase III Endpoint
2020-04-20 06:59:00 | CORRECTED-Bristol Myers says Opdivo performs well in kidney, lung cancer trials
2020-04-20 06:59:00 | Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® nivolumab in Combination with CABOMETYX® cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma
2020-04-09 11:40:03 | EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
2020-03-26 15:41:53 | Were These Hedge Funds Right About Selling Exelixis, Inc. EXEL?
2020-03-26 11:30:03 | Why Is Exelixis EXEL Down 15.6% Since Last Earnings Report?
2020-03-24 11:40:03 | EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
2020-03-17 07:02:25 | A Sliding Share Price Has Us Looking At Exelixis, Inc.'s NASDAQ:EXEL P/E Ratio
2020-03-02 16:05:00 | Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors
2020-02-27 00:31:17 | Edited Transcript of EXEL earnings conference call or presentation 25-Feb-20 10:00pm GMT
2020-02-26 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations in March
2020-02-26 10:03:03 | Exelixis EXEL Beats on Earnings, Misses on Sales in Q4
2020-02-25 18:35:11 | Exelixis EXEL Tops Q4 Earnings Estimates
2020-02-21 11:30:04 | Exelixis EXEL to Report Q4 Earnings: What's in the Cards?
2020-02-19 07:28:50 | The Exelixis NASDAQ:EXEL Share Price Has Soared 689%, Delighting Many Shareholders
2020-02-12 14:10:26 | 3 Mid-Cap Growth Stocks to Buy
2020-02-11 17:50:10 | Exelixis EXEL Outpaces Stock Market Gains: What You Should Know
2020-02-04 17:50:10 | Exelixis EXEL Gains But Lags Market: What You Should Know
2020-01-28 09:52:32 | How Alameda — again — became a biotech hotspot